Cancer prevention trial of a synergistic mixture of green tea concentrate plus Capsicum (CAPSOL-T) in a random population of subjects ages 40-84

Clinical Proteomics

Dorothy M Morré²  D James Morré²  Claudia Hanau¹ 

[1] HANAU Health Services, Inc, 160 Sagamore Parkway W, West Lafayette, IN 47906, USA;MorNuCo, Inc, 1201B Cumberland Avenue, West Lafayette, IN 47906, USA

关键词: ONCOblot Tissue of Origin Cancer Test;    Capsol-T®;    Green tea concentrate;    Early intervention;    Early detection;    Prevention trial;    Curative prevention®;    Cancer;   

Others  :  803330
DOI  :  10.1186/1559-0275-11-2

 received in 2013-07-12, accepted in 2013-12-10,  发布年份 2014

【 摘 要 】

Background

Experts agree that one of the more promising strategies in cancer management is early detection coupled with early intervention. In this study, we evaluated an early cancer detection strategy of cancer presence based on serum levels of the cancer-specific transcript variants of ENOX2 in serum coupled with an ENOX2-targeted nutraceutical preparation of green tea concentrate plus Capsicum (Capsol-T®) as a strategy of Curative Prevention® involving early detection coupled with early intervention in early stage cancer when in its most susceptible and manageable stages.

Experimental design

One hundred ten (110) subjects were tested for cancer presence using the ONCOblot® Tissue of Origin 2-D gel/western blot protocol for detection of serum presence of transcript variants of the ENOX2 protein. Subjects testing positive for ENOX2 received 350 mg of Capsol-T® in capsule form every 4 h including during the night for periods of at least 3 to 6 months or longer after which they were again tested for ENOX2 presence using the ONCOblot® Tissue of Origin Cancer Test protocol.

Results

Of the 110 subjects, both male and female, ages 40 to 84, with no evidence of clinical symptoms of cancer, 40% were positive for ENOX2 presence in the ONCOblot® Tissue of Origin Cancer Test. After completion of 3 to 17 months of Capsol-T® use, 94% of subjects subsequently tested negative for ENOX2 presence.

Conclusions

Oral Capsol-T® is well tolerated and, for ENOX2 presence in serum in the absence of clinical cancer symptoms, is consistently effective in reducing the serum ENOX2 levels to below detectable limits.

【 授权许可】

   
2014 Hanau et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]American Cancer Society: Facts and Figures 2013. Atlanta: American Cancer Society; 2013.
• [2]Siegel R, Naidhadham D, Jemal A: Cancer statistics 2012. CA. A Cancer J Clin 2012, 62(1):10-29.
• [3]Howlader N, Noone AM, Krapcho M, Garshel J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, in KA C (Eds): ISEER In Cancer Statistics Review, 1975-2010. Bethesda, MD: Nat Cancer Ins; 2013. http://seer.cancer.gov/csr/1975_2010/ webcite. Based on November 2012 SEER data submission, posted to the SEER web site
• [4]Coghlin C, Murray GI: Current and emerging concepts in tumor metastasis. J Pathol 2010, 222(1):1-35.
• [5]Morré DJ, Morré DM: Early detection: an opportunity for cancer prevention through early intervention. In Cancer Prevention. Edited by Georgakilas AG. Rijeka: In Tech; 2012:389-402.
• [6]Chueh PJ, Kim C, Cho N, Morré DM, Morré DJ: Molecular cloning and characterization of a tumor-associated, growth-related, and time-keeping hydroquinone (NADH) oxidase (tNOX) of the HeLa cell surface. Biochemistry 2002, 41(11):3732-3741.
• [7]Morré DJ, Morré DM: ECTO-NOX Proteins. New York: Springer; 2013:507.
• [8]Cho N, Chueh PJ, Kim C, Caldwell S, Morré DM, Morré DJ: Monoclonal antibody to a cancer- specific and drug-responsive hydroquinone (NADH) oxidase from the sera of cancer patients. Cancer Immunol Immunother 2002, 51(3):121-129.
• [9]Morré DJ, Morré DM: Cell surface NADH oxidases (ECTO-NOX proteins) with roles in cancer, cellular time-keeping, growth, aging and neurodegenerative diseases. Free Radic Res 2003, 37(18):795-808.
• [10]Tang X, Tian Z, Chueh PJ, Chen S, Morré DM, Morré DJ: Alternative splicing as the basis for specific localization of tNOX, a unique hydroquionone (NADH) oxidase, to the cancer cell surface. Biochemistry 2007, 46(43):12,337-12,346.
• [11]Tang X, Morré DJ, Morré DM: Antisense experiments demonstrate an exon 4 minus splice variant mRNA as the basis for expression of tNOX, a cancer-specific cell surface protein. Oncol Res 2008, 16(12):557-567.
• [12]Davies SL, Bozzo J: Spotlight on tNOX: a tumor-selective target for cancer therapies. Drug News Prospect 2006, 19(4):223-225.
• [13]Del Principe D, Avigalo L, Savini I, Catani MV: Trans-plasma membrane electron transport in mammals: functional significance in health and disease. Antioxid Redox Signal 2011, 14(11):2289-2318.
• [14]Hostetler B, Weston N, Kim C, Morré DM, Morré DJ: Cancer site-specific isoforms of ENOX2 (tNOX), a cancer-specific cell surface oxidase. Clin Proteomics 2009, 5:46-51.
• [15]Pisters KM, Newman RA, Coldman B, Shin DM, Khuri FR, Hong WK, Glisson BS, Lee JS: A Phase 1 trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol 2001, 19(6):1830-1838.
• [16]Jatoi A, Ellison N, Burch PA, Sloan JA, Dakhil SR, Novotny P, Tan W, Fitch TR, Rowland KM, Young CY, Flynn PJ: A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 2003, 97(6):1442-1446.
• [17]Yagiz K, Morré DJ, Morré DM: Transgenic mouse expressing the cancer-specific tNOX protein has an enhanced growth and acquired drug-response phenotype. J Nutr Biochem 2006, 17(11):750-759.
• [18]Golden EB, Lam PY, Kardosh A, Faffney KJ, Cadenas E, Louie SG, Patasis NA, Chen TC, Schontal AH: Green tea polyphenols block the anticancer effects bortezomib and other boronic acid-based proteasome inhibitors. Blood 2009, 113(23):5927-5937.
• [19]Weinberg RA: The Biology of Cancer, Garland Science, New York. (Fig. 11.1, Courtesy of WK Hong compiled from SEER Cancer Statistics Review). New York: Garland Science; 1996:796.
• [20]Jin XP, Peng JB, Pang H, Zhu YN, Fei J, Gup LH: A mRNA molecule encoding truncated excitatory amino acid carrier 1 (EAAC1) protein (EAAC2) is transcribed from an independent promoter but not as an alternative splicing event. Cell Res 2002, 12(3–4):257-262.
• [21]Michaelson J, Salija S, Moore B, Weber G, Halpern E, Garland A, Kopans DB, Hughes K: Estimates of the sizes at which breast cancers become detectable on mammograms and clinical grounds. J Women’s Imaging 2003, 5(1):3-10.
• [22]Morré DJ, Bridge A, Wu LY, Morré DM: Preferential inhibition by (-)-epigallocatechin-3-gallate of the cell surface NADH oxidase and growth of transformed cells in culture. Biochem Pharmacol 2000, 60(7):937-946.
• [23]Morré DJ, Chueh P-J, Morré DM: Capsaicin inhibits preferentially the NADH oxidase and growth of transformed cells in culture. Proc Natl Acad Sci USA 1995, 92(6):1831-1835.
• [24]Morré DJ, Morré DM, Sun H, Cooper R, Chang J, Janle EM: Tea catechin synergies in inhibition of cancer cell proliferation and of a cancer-specific cell surface oxidase (ECTO-NOX). Pharmacol Toxicol 2003, 92(5):234-241.
• [25]Morré DJ, Morré DM: Synergistic Capsicum-tea mixtures with anticancer activity. J Pharm Pharm 2003, 55(7):987-994.
• [26]Janle E, Morré DM, Morré DJ, Zhou Q, Chang H, Zhu Y: Pharmacokinetics of green tea catechins in extract and sustained-release preparations. J Dietary Suppl 2008, 5(3):248-263.
• [27]Fujiki H: Two stages of cancer prevention with green tea. J Cancer Res Clin Oncol 1999, 125(11):589-597.
• [28]Nakachi K, Matsuyama S, Miyake S, Sugaruma M, Imai K: Preventive effects of drinking green tea on cancer and cardiovascular disease: epidemiological evidence for multiple targeting prevention. Biofactors 2000, 13(1–4):49-54.
• [29]Unno T, Takeo T: Absorption of (-)-epigallocatcechin gallate into the circulation system of rats. Biosci Biotechnol Biochem 1995, 59(8):1558-1559.
• [30]Zhu M, Chen Y, Li RC: Oral absorption and bioavailability of tea catechins. Planta Med 2000, 66(5):444-447.
• [31]Warden BA, Smith LA, Beecher GR, Balentine DA, Clevidence BA: Catechins are bioavailable in men and women drinking black tea throughout the day. J Nutr 2001, 131(6):1731-1737.
• [32]Nakagawa KMT: Absorption and distribution of tea catechin, (-)-epigallocatechin-3-gallate, in the rat. J Nutr Sci Vitaminol 1997, 43(6):679-684.
• [33]Yang CS: Inhibition of carcinogenesis by tea. Nature 1997, 389(6647):134-135.
• [34]Nakagawa K, Okuda S, Miyazawa T: Dose-dependent incorporation of tea catechins, (-)- epigallocatechin-3-gallate and (-)-epigallocatechin, into human plasma. Biosci Biotechnol Biochem 1997, 61(12):1981-1985.
• [35]van het Hof KH, Wiseman SA, Chang CS, Tijburg BM: Plasma and lipoprotein levels of tea catechins following repeated tea consumption. Proc Soc Exp Biol Med 1999, 220(4):203-209.
• [36]Yang CS, Chen L, Lee MJ, Balentine D, Kyo MC, Schantz SP: Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer Epidemiol Biomarkers Prev 1998, 7(4):351-354.
• [37]Chueh PJ, Wu L-Y, Morré DM, Morré DJ: tNOX is both necessary and sufficient as a cellular target for the anticancer actions of capsaicin and the green tea catechin (-)-epigallocatechin-3-gallate. Biofactors 2004, 20(4):235-249.
• [38]Cooper RD, Morré DJ, Morré DM: Medicinal benefits of green tea: Part II. Review of anticancer properties. J Altern Comp Med 2005, 11(4):639-652.
• [39]Isbrucker RA, Bausch J, Edwards JA, Wolz E: Safety studies on epigallocatechin gallate (EGCg) preparations. Part 1: genotoxicity. Food Chem Toxicol 2006, 44(5):626-635.
• [40]Isbrucker RA, Edwards JA, Wolz E, Davidovich A, Bausch J: Safety studies on epigallocatechin gallate (EGCg) preparations. Part 2: dermal, acute and short-term toxicity studies. Food Chem Toxicol 2006, 44(5):636-650.
• [41]Isbrucker RA, Edwards JA, Wolz E, Davidovich A, Bausch J: Safety studies on epigallocatechin gallate (EGCg) preparations. Part 3: teratogenicity and reproductive toxicity studies in rats. Food Chem Toxicol 2006, 44(5):651-661.
• [42]National Center for Complementary and Alternative Medicine: Botanical Fact Sheet, Green Tea, Office of Dietary Supplements. Bethesda: National Institues of Health; 2012:2.
• [43]De Luca T, Morré DM, Morré DJ: Reciprocal relationship between cytosolic NADH and ENOX2 inhibition triggers sphingolipid-induced apoptosis in HeLa cells. J Cell Biochem 2010, 110(6):1504-1511.